The 2nd Annual Drug Repositioning Congress Europe 2013 is a conference and exhibition dedicated to strategies for drug development, indication expansion, lifecycle extension, re-purposing, re-profiling or re-tasking existing biological candidates, including:
- Derisking R&D
- Reducing R&D expenditure
- Reviving failed drug candidates and market withdrawn drugs
- Enhancing Product Life Cycle Management
- Boosting industry productivity
The 2nd Annual Drug Repositioning Congress Europe 2013 brings together:
- Mid Cap / SME Biotechs
- Pharmaceutical Companies
- Government / Regulatory Bodies
- Specialist Repositioning Companies
- Bioinformatics Companies
- Academic/ Research Institutes
- Equipment Manufacturers
- Contract Research Organisations
- Law Firms
- Consultants
